Planview Recognized as a Leader in 2020 Gartner® Magic Quadrant for Enterprise Agile Planning Tools
23.4.2020 20:11:00 EEST | Business Wire | Press release
Planview® today announced it is named a Leader in the 2020 Gartner Magic Quadrant for Enterprise Agile Planning Tools. The report evaluated Planview’s Lean and Agile Delivery solution and positioned the company highest in the Leaders quadrant for Ability to Execute.
“Every organization today has their own transformation story, even Planview. We rewired ourselves to pivot and focus on holistic portfolio and work management solutions, doubling down on Lean and Agile. Core to our vision is to serve enterprises at all stages of Agile transformation, helping them transform on their terms and timeline,” said Patrick Tickle, Planview Chief Product Officer. “We’re excited to be recognized by Gartner.”
According to Gartner, “Enterprise-class agile development is a natural evolution of project-level agile to support the demands of large-scale software management. Agile processes are highly accelerated and iterative. The information needs of agile teams often differ from those of their leadership. This has led to the use of a variety of tools: some for the teams, others for management.”
Planview offers a full spectrum of Portfolio and Work Management solutions that are uniquely positioned to help organizations successfully accelerate on-strategy delivery. With a focus on bringing together leadership solutions spanning Agile and PPM, Planview is the platform partner for enterprise class organizations navigating the transformation of work, portfolio management, and the shift to product-centricity.
“We think Planview’s Leader position shows exactly where Agile is going,” said Dr. Mik Kersten, Tasktop CEO and best-selling author of Project to Product. “Enterprise needs for Agile at scale mean that team-level functionality is no longer enough. It has been amazing to see a leading PPM vendor make such a profound and impactful shift from project to product in their own portfolio, and helping others do the same. As a strategic partner, we are honored to be part of the journey and look forward to Planview driving results in the market at this critical time for organizations needing to shift to software and digital innovation.”
“Working with best-in-class partners like Planview represents our commitment to helping enterprises deliver competitive solutions to its customers in the shortest sustainable lead time,” said Dean Leffingwell, creator of SAFe and co-founder of Scaled Agile, Inc. “Planview’s experience in the Lean Portfolio Management and enterprise Kanban space is an invaluable asset for organizations looking to effectively connect their portfolio to business strategy.”
“When Planview and LeanKit came together in 2017, we shared this vision; it’s why I wanted us to become a part of the Planview family. Our goal from the beginning was to build a Lean and Agile Delivery solution that is pragmatic and reflects the realities of Agile transformation. Transformation takes time, and organizations need a partner that can see and understand the whole journey, even the ugly parts,” explains Jon Terry, former LeanKit co-Founder and current Planview Chief Lean-Agile Evangelist.
To learn more about the Planview Lean and Agile Delivery Solution visit: planview.com/lean-agile-delivery.
Additional Resources:
- Blog: Lean into the Changing World of Work
- Guide: The Ultimate Lean and Agile Software Solution Buyer’s Guide
- Whitepaper: 7 Benefits of Scaling Agile
- 3 Minute Pathfinder: Lean-Agile Pathfinder
Gartner, Magic Quadrant for Enterprise Agile Planning Tools by Keith Mann, Mike West, Bill Blosen, Akis Sklavounakis, Deacon D.K Wan, April 21, 2020
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose
About Planview
Planview has one focus: enabling the transformation journey as organizations rewire strategy to delivery in today’s fast-paced, highly disruptive markets. Our solutions uniquely help organizations navigate this journey and accelerate on-strategy delivery at enterprise scale. Planview’s full spectrum of Portfolio Management and Work Management solutions create organizational focus on the strategic outcomes that matter and empower teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enable customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, Planview has more than 700 employees supporting 3,500 customers and 1 million users worldwide. For more information, visit https://www.planview.com/.
Planview and LeanKit are registered trademarks of Planview, Inc. and the Planview logo is a trademark of Planview, Inc. All other trademarks are property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200423005753/en/
Contact information
Leslie Marcotte
lmarcotte@planview.com
719-439-4921
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom